St. Jude Medical has been granted CE Mark approval of its EnligHTN renal denervation system.
Renal denervation is an ablation procedure that seeks to reduce blood pressure in patients with hypertension that is resistant to medical therapy. Clinical data from the EnligHTN I trial about the safety and efficacy of this renal denervation technology will be presented on May 16 at EuroPCR in Paris.
Using the EnligHTN system, an ablation catheter delivers radiofrequency energy to create lesions along the renal sympathetic nerves. The system uses multi-electrode ablation technology. With the basket design, the placement of the ablation catheter allows a pattern of four ablations in 90-second intervals.
St. Jude is based in St. Paul, Minn.